亚太地区冻干注射药物市场 – 行业趋势及 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

亚太地区冻干注射药物市场 – 行业趋势及 2028 年预测

  • Pharmaceutical
  • Published Report
  • Jun 2021
  • Asia-Pacific
  • 350 页面
  • 桌子數: 283
  • 图号: 49

亚太地区冻干注射剂市场,按包装(小瓶、双室注射器、双室药筒等)、药品类别(抗感染药、抗肿瘤药、利尿药、质子泵抑制剂、麻醉药、抗凝剂、非甾体抗炎药、皮质类固醇等)、形式(粉末和液体)、适应症(肿瘤学、自身免疫性疾病、激素紊乱、呼吸系统疾病、胃肠道疾病、皮肤病、眼科疾病等)、给药途径(静脉/输液、肌肉注射等)、最终用户(医院、诊所、家庭医疗保健等)、分销渠道(直接招标、零售销售等)、国家(日本、中国、澳大利亚、印度、韩国、新加坡、印度尼西亚、泰国、马来西亚、菲律宾、越南、亚太其他地区)划分,行业趋势及预测2028 年。

亚太地区冻干注射剂市场

市场分析与洞察:亚太地区冻干注射药物市场

预计冻干注射药物市场将在 2021 年至 2028 年的预测期内实现市场增长。Data Bridge Market Research 分析称,该市场以 7.7% 的复合年增长率增长,预计在 2021 年至 2028 年的预测期内将达到 13.5181 亿美元。大量市场参与者参与提供冻干注射药物产品,并通过创新为冻干注射药物市场的增长铺平了道路。

冻干是一种从成品中除去水分的冷冻干燥方法。冻干的输出产品在高真空下冷冻。在生物技术和制药行业中,冻干工艺用于生产保质期较长的高质量产品。

慢性健康状况的增加、老年人和患有心脏和神经系统缺陷的总人口的增加、冻干注射药物管道的扩大、使用预充稀释剂注射器注射冻干注射药物的风险的降低、以及由于研发增加而带来的技术进步,正在推动亚太地区冻干注射药物市场的发展。

此外,冻干技术可以安全地运输和储存这些物质,直到需要它们为止。由于安全问题增加,注射药物现在必须进行冻干。经过长时间的储存,冻干注射药物已被证明比其他干燥物品更安全、更方便使用。

冻干注射药物市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息,分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况,请联系我们获取分析师简报,我们的团队将帮助您创建收入影响解决方案,以实现您的预​​期目标。

亚太地区冻干注射剂市场

亚太地区冻干注射剂市场范围和市场规模

冻干注射药物市场根据包装、药物类别、形式、适应症、给药途径、最终用户和分销渠道分为七个显著的细分市场。细分市场之间的增长有助于您分析利基市场的增长和进入市场的策略,并确定您的核心应用领域和目标市场的差异。

  • 根据包装,冻干注射剂市场分为小瓶、双室注射器、双室药筒和其他。2021 年,小瓶部分预计将在冻干注射剂市场中占据主导地位,因为大多数冻干注射剂都采用小瓶包装,因此它在市场上具有影响力且不断增长。
  • 根据药物类别,冻干注射药物市场细分为抗感染、抗肿瘤、利尿剂、质子泵抑制剂、麻醉剂、抗凝剂、非甾体抗炎药、皮质类固醇等。2021 年,抗感染药物预计将在冻干注射药物市场占据主导地位,因为亚洲地区慢性病发病率高,这促进了对抗生素和抗病毒药物的需求。
  • 根据形式,冻干注射剂市场分为粉末和液体。2021 年,粉末部分预计将主导冻干注射剂市场,因为它在亚太地区的储存和运输中得到广泛使用。
  • 根据适应症,冻干注射药物市场细分为肿瘤学、自身免疫性疾病、激素紊乱、呼吸系统疾病、胃肠道疾病、皮肤病、眼科疾病等。2021 年,肿瘤学领域预计将主导冻干注射药物市场,因为冻干注射药物在亚洲地区的肿瘤学中使用率很高。
  • 根据给药途径,冻干注射药物市场细分为静脉/输液、肌肉注射和其他。2021 年,静脉/输液部分预计将主导冻干注射药物市场,因为通过这种给药途径药物的生物利用度为 100%。
  • 根据最终用户,冻干注射药物市场分为医院、诊所、家庭医疗保健和其他。由于亚洲地区拥有熟练的专业人员,预计 2021 年医院部门将主导冻干注射药物市场。
  • 根据分销渠道,冻干注射剂市场细分为直接招标、零售销售和其他。2021 年,直接招标部分预计将主导冻干注射剂市场,因为亚太地区对直接招标的需求很高。

冻干注射药物市场国家级分析

对冻干注射药物市场进行了分析,并按上述国家、包装、药品类别、形式、适应症、给药途径、最终用户和分销渠道提供了市场规模信息。

亚太冻干注射药物市场涵盖的国家包括日本、中国、澳大利亚、印度、韩国、新加坡、印度尼西亚、泰国、马来西亚、菲律宾、越南和亚太其他地区。

由于慢性健康状况的增加和患有慢性病的老年人口的增加,预计中国将占据市场主导地位。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了亚太品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。

制造商推出的新产品为冻干注射药物市场参与者创造了新的机会

冻干注射药物市场还为您提供每个国家美容行业增长的详细市场分析,包括冻干注射药物市场的销售、冻干注射药物市场发展的影响以及监管环境的变化及其对冻干注射药物市场的支持。数据涵盖 2010 年至 2019 年的历史时期。

竞争格局和冻干注射药物市场份额分析

冻干注射药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对冻干注射药物市场的关注有关。

亚太地区冻干注射药物市场的主要冻干注射药物供应商包括 Affy Pharma Pvt Ltd.、Genex Pharma、AuroMedics Pharma LLC Pharma LLC(Aurobindo Pharma 的子公司)、Astellas Pharma US, Inc.(Astellas Pharma Inc. 的子公司)、Aristopharma Ltd.、Pfizer Inc.、Sanofi、Celon Laboratories Pvt. Ltd. 和 Baxter 等。DBMR 分析师了解竞争优势,并为每个竞争对手分别提供竞争分析。

全球各地的公司也签订了许多合同和协议,这也加速了冻干注射药物市场的发展。

  • 2019 年 11 月,辉瑞公司宣布其 Upjohn 部门与 Mylan NV 合并,成立一家名为 Viatris Inc. 的新公司。该公司业务部门与 Mylan NV 的合并增加了其产品组合,从而增加了市场对其产品的需求。

市场参与者的合作、合资和其他策略正在增强公司在冻干注射药物市场的市场,这也为组织改善其在冻干注射药物市场的供应提供了好处。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PACKAGING LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK

5 EPIDEMIOLOGY

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN CHRONIC HEALTH CONDITIONS

6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE

6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES

6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS

6.1.5 TECHNOLOGICAL ADVANCEMENTS

6.2 RESTRAINTS

6.2.1 RISK OF NEEDLESTICK INJURIES

6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE

6.3 OPPORTUNITIES

6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS

6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS

6.3.3 QUALITY CONCERNS

6.4 CHALLENGES

6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS

6.4.2 TIME-CONSUMING PROCESS AND HIGH COST

7 IMPACT OF COVID-19 ON THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT IN DEMAND

7.3 IMPACT ON SUPPLY

7.4 STRATEGIC INITIATIVE

7.5 CONCLUSION

8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING

8.1 OVERVIEW

8.2 VIALS

8.3 DUAL-CHAMBER SYRINGES

8.4 DUAL-CHAMBER CARTRIDGES

8.5 OTHERS

9 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS

9.1 OVERVIEW

9.2 ANTI-INFECTIVE’S

9.2.1 ANTIBIOTICS

9.2.1.1 Azithromycin

9.2.1.2 Doxycycline

9.2.1.3 Vancomycin

9.2.1.4 Polymyxin B

9.2.1.5 Piperacillin

9.2.1.6 Tazobactam

9.2.1.7 Others

9.2.2 ANTIFUNGAL

9.2.2.1 Mycamine

9.2.2.2 Caspofungin Acetate

9.2.2.3 Isavuconazonium Sulfate

9.2.2.4 Amphotericin

9.2.2.5 Others

9.2.3 ANTIVIRAL

9.2.3.1 Acyclovir

9.2.3.2 Ganciclovir

9.2.3.3 Remdesivir

9.2.3.4 Others

9.2.4 OTHERS

9.3 ANTINEOPLASTIC

9.3.1 METHOTREXATE

9.3.2 GEMCITABINE

9.3.3 CYTARABINE

9.3.4 FLUDARABINE

9.3.5 DOXORUBICIN

9.3.6 OXALIPLATIN

9.3.7 ZOLEDRONIC ACID

9.3.8 OTHERS

9.4 DIURETICS

9.4.1 CHLOROTHIAZIDE

9.4.2 ETHACRYNIC ACID

9.4.3 ACETAZOLAMIDE

9.4.4 OTHERS

9.5 PROTON PUMP INHIBITOR

9.5.1 ESOMEPRAZOLE SODIUM

9.5.2 PANTOPRAZOLE SODIUM

9.5.3 OMEPRAZOLE

9.5.4 OTHERS

9.6 ANESTHETIC

9.6.1 VECURONIUM BROMIDE

9.6.2 SODIUM THIOPENTAL

9.6.3 LIDOCAINE

9.6.4 OTHERS

9.7 ANTICOAGULANT

9.7.1 COUMADIN

9.7.2 UROKINASE

9.7.3 ANTITHROMBIN (RECOMBINANT)

9.7.4 APIXABAN

9.7.5 RIVAROXABAN

9.7.6 OTHERS

9.8 NSAID’S

9.8.1 INDOMETHACIN

9.8.2 IBUPROFEN

9.8.3 DICLOFENAC

9.8.4 KETOROLAC

9.8.5 OTHERS

9.9 CORTICOSTEROIDS

9.9.1 HYDROCORTISONE

9.9.2 METHYLPREDNISOLONE

9.9.3 OTHERS

9.1 OTHERS

10 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM

10.1 OVERVIEW

10.2 POWDER

10.3 LIQUID

11 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION

11.1 OVERVIEW

11.2 ONCOLOGY

11.3 AUTOIMMUNE DISEASES

11.4 HORMONAL DISORDERS

11.5 RESPIRATORY DISEASES

11.6 GASTROINTESTINAL DISORDERS

11.7 DERMATOLOGICAL DISORDERS

11.8 OPHTHALMIC DISEASES

11.9 OTHERS

12 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION

12.1 OVERVIEW

12.2 INTRAVENOUS/INFUSION

12.3 INTRAMUSCULAR

12.4 OTHERS

13 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 CLINICS

13.4 HOME HEALTHCARE

13.5 OTHERS

14 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 DIRECT TENDERS

14.3 RETAIL SALES

14.4 OTHERS

15 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION

15.1 ASIA-PACIFIC

15.1.1 JAPAN

15.1.2 CHINA

15.1.3 SOUTH KOREA

15.1.4 INDIA

15.1.5 AUSTRALIA

15.1.6 SINGAPORE

15.1.7 THAILAND

15.1.8 MALAYSIA

15.1.9 INDONESIA

15.1.10 PHILIPPINES

15.1.11 VIETNAM

15.1.12 REST OF ASIA-PACIFIC

16 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 PFIZER INC.

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 CIPLA INC.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 NOVARTIS AG

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 BAXTER

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 ZYDUS CADILA

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 AFFY PHARMA PVT LTD.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 AMNEAL PHARMACEUTICALS LLC

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 ARISTOPHARMA LTD.

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENT

18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 CELON LABORATORIES PVT.LTD.

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENT

18.14 CIRONDRUGS

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 GENEX PHARMA

18.15.1 COMPANY SNAPSHOT

18.15.2 PRODUCT PORTFOLIO

18.15.3 RECENT DEVELOPMENT

18.16 GILEAD SCIENCES, INC.

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENTS

18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENTS

18.18 OTSUKA AMERICA PHARMACEUTICAL, INC

18.18.1 COMPANY SNAPSHOT

18.18.2 PRODUCT PORTFOLIO

18.18.3 RECENT DEVELOPMENTS

18.19 SANOFI

18.19.1 COMPANY SNAPSHOT

18.19.2 REVENUE ANALYSIS

18.19.3 PRODUCT PORTFOLIO

18.19.4 RECENT DEVELOPMENT

18.2 VIATRIS INC.

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

19 QUESTIONNAIRE

20 RELATED REPORTS

表格列表

TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS

TABLE 2 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 3 ASIA-PACIFIC VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 ASIA-PACIFIC DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 ASIA-PACIFIC DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 9 ASIA-PACIFIC ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 ASIA-PACIFIC ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 11 ASIA-PACIFIC ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 12 ASIA-PACIFIC ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 13 ASIA-PACIFIC ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 14 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 16 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 18 ASIA-PACIFIC PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 ASIA-PACIFIC PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 20 ASIA-PACIFIC ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 ASIA-PACIFIC ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 22 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 24 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 26 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 28 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 30 ASIA-PACIFIC POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 ASIA-PACIFIC LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 33 ASIA-PACIFIC ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 34 ASIA-PACIFIC AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 ASIA-PACIFIC HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 ASIA-PACIFIC RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 ASIA-PACIFIC GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 ASIA-PACIFIC DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 ASIA-PACIFIC OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 42 ASIA-PACIFIC INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 43 ASIA-PACIFIC INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 ASIA-PACIFIC HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 ASIA-PACIFIC CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 ASIA-PACIFIC HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 50 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 51 ASIA-PACIFIC DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 52 ASIA-PACIFIC RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 53 ASIA-PACIFIC OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 54 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 55 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 56 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 57 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 58 ASIA-PACIFIC ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 59 ASIA-PACIFIC ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 60 ASIA-PACIFIC ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 61 ASIA-PACIFIC ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 62 ASIA-PACIFIC ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 63 ASIA-PACIFIC DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 64 ASIA-PACIFIC PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 65 ASIA-PACIFIC ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 66 ASIA-PACIFIC ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 67 ASIA-PACIFIC NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 68 ASIA-PACIFIC CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 69 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 70 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 71 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 73 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 74 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 75 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 76 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 77 JAPAN ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 78 JAPAN ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 79 JAPAN ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 80 JAPAN ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 81 JAPAN ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 82 JAPAN DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 83 JAPAN PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 84 JAPAN ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 85 JAPAN ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 86 JAPAN NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 87 JAPAN CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 88 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 89 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 90 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 JAPAN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 94 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 95 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 96 CHINA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 97 CHINA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 98 CHINA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 99 CHINA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 100 CHINA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 101 CHINA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 102 CHINA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 103 CHINA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 104 CHINA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 105 CHINA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 106 CHINA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 107 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 108 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 109 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 110 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 111 CHINA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 112 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 113 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 114 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 115 SOUTH KOREA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 116 SOUTH KOREA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 117 SOUTH KOREA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 118 SOUTH KOREA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 119 SOUTH KOREA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 120 SOUTH KOREA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 121 SOUTH KOREA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 122 SOUTH KOREA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 123 SOUTH KOREA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 124 SOUTH KOREA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 125 SOUTH KOREA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 126 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 127 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 128 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 129 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 130 SOUTH KOREA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 131 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 132 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 133 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 134 INDIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 135 INDIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 136 INDIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 137 INDIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 138 INDIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 139 INDIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 140 INDIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 141 INDIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 142 INDIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 143 INDIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 144 INDIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 145 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 146 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 147 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 148 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 149 INDIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 150 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 151 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 152 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 153 AUSTRALIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 154 AUSTRALIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 155 AUSTRALIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 156 AUSTRALIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 157 AUSTRALIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 158 AUSTRALIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 159 AUSTRALIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 160 AUSTRALIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 161 AUSTRALIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 162 AUSTRALIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 163 AUSTRALIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 164 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 165 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 166 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 167 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 168 AUSTRALIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 169 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 170 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 171 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 172 SINGAPORE ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 173 SINGAPORE ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 174 SINGAPORE ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 175 SINGAPORE ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 176 SINGAPORE ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 177 SINGAPORE DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 178 SINGAPORE PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 179 SINGAPORE ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 180 SINGAPORE ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 181 SINGAPORE NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 182 SINGAPORE CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 183 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 184 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 185 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 186 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 187 SINGAPORE LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 188 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 189 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 190 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 191 THAILAND ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 192 THAILAND ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 193 THAILAND ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 194 THAILAND ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 195 THAILAND ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 196 THAILAND DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 197 THAILAND PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 198 THAILAND ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 199 THAILAND ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 200 THAILAND NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 201 THAILAND CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 202 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 203 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 204 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 205 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 206 THAILAND LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 207 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 208 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 209 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 210 MALAYSIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 211 MALAYSIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 212 MALAYSIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 213 MALAYSIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 214 MALAYSIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 215 MALAYSIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 216 MALAYSIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 217 MALAYSIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 218 MALAYSIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 219 MALAYSIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 220 MALAYSIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 221 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 222 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 223 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 224 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 225 MALAYSIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 226 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 227 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 228 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 229 INDONESIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 230 INDONESIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 231 INDONESIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 232 INDONESIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 233 INDONESIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 234 INDONESIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 235 INDONESIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 236 INDONESIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 237 INDONESIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 238 INDONESIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 239 INDONESIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 240 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 241 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 242 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 243 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 244 INDONESIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 245 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 246 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 247 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 248 PHILIPPINES ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 249 PHILIPPINES ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 250 PHILIPPINES ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 251 PHILIPPINES ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 252 PHILIPPINES ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 253 PHILIPPINES DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 254 PHILIPPINES PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 255 PHILIPPINES ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 256 PHILIPPINES ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 257 PHILIPPINES NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 258 PHILIPPINES CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 259 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 260 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 261 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 262 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 263 PHILIPPINES LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 264 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

TABLE 265 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 266 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)

TABLE 267 VIETNAM ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 268 VIETNAM ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 269 VIETNAM ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 270 VIETNAM ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 271 VIETNAM ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 272 VIETNAM DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 273 VIETNAM PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 274 VIETNAM ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 275 VIETNAM ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 276 VIETNAM NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 277 VIETNAM CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)

TABLE 278 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)

TABLE 279 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 280 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 281 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 282 VIETNAM LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 283 REST OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: ASIA-PACIFIC VS. REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID

FIGURE 11 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION

FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028

FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR THE LYOPHILIZED INJECTABLE DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET

FIGURE 16 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020

FIGURE 17 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)

FIGURE 18 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)

FIGURE 19 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 20 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020

FIGURE 21 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)

FIGURE 22 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)

FIGURE 23 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE

FIGURE 24 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020

FIGURE 25 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)

FIGURE 26 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)

FIGURE 27 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE

FIGURE 28 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020

FIGURE 29 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 30 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 31 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 32 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 33 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 34 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 35 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020

FIGURE 37 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 41 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)

FIGURE 45 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)

FIGURE 46 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)

FIGURE 47 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)

FIGURE 48 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)

FIGURE 49 ASIA-PACIFIC LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.